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To determine the usefulness of tyrosine phosphorylation in evaluating biological characteristics, we attempted to evaluate the
relationship between the amount of phosphorylated tyrosine-containing proteins and clinicopathological factors, cell
proliferation and outcome in non-small cell lung cancer. To evaluate phosphorylated tyrosine-containing proteins we used 96
surgically resected materials of non-small cell lung cancer and normal peripheral lung, while immunohistochemical evaluation
was performed. Cell proliferating ability was evaluated using the labelling index of proliferating cell nuclear antigen-positive
nuclear staining cells. There were statistically signiﬁcant differences between the expression levels of phosphorylated tyrosine-
containing proteins of normal and cancerous tissues (P50.0001). Evaluations based on clinicopathological factors apart from
histopathological differentiation, showed no statistically signiﬁcant differences of phosphorylated tyrosine-containing proteins
expression. However, phosphorylated tyrosine-containing proteins correlated with cell proliferation activity evaluated (P(Low,
High)50.0001; P(Low, Int) 50.0001; P(Int, High)50.0001). Furthermore, non-small cell lung cancer cases with high expression and
intermediate expression of phosphorylated tyrosine-containing proteins had a signiﬁcantly shorter disease-free postoperative
survival than those with low expression of phosphorylated tyrosine-containing proteins using log-rank analysis (P(Low, Int)
50.0028; P(Low, High)=0.0002). Furthermore, phosphorylated tyrosine-containing proteins expression level statistically
contributed to disease-free survival in Cox’s proportional hazard model. Therefore, phosphorylated tyrosine-containing
proteins in non-small cell lung cancer tissues seem to reﬂect its biological malignancy, and this evaluation may be valuable for
constructing the most appropriate therapeutic strategy.
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Primary lung cancer is one of the most malignant solid tumours. In
spite of current improvements in combined therapy, its incidence
and mortality rates are still increasing in Japan. Since the clinical
courses of lung cancer patients are extremely varied, and an under-
standing of the individual characteristics of the tumour could be
important, and the evaluation of useful biomarker may be valuable
for constructing the most appropriate therapeutic strategy.
Recently, extensive studies have been performed to identify
oncogenes that encode tyrosine-protein kinase in human cancer
cells (Kiyokawa et al, 1994; Peng and Cartwright, 1995; Goodman
et al, 2001) and certain evidence suggests that oncogenes of the
tyrosine kinase-type are involved in the tumorigenesis (Scrimgeour
et al, 1997; Hung and Elliott, 2001) and immortalisation (McCor-
mack et al, 1997; Vogt et al, 1989) of various types of human
cancers. Aberrant expression of epidermal growth factor (EGF)
receptors and HER2/neu proto-oncogene have been reported in
primary lung cancer (Dazzi et al, 1989; Schneider et al, 1989; Kern
et al, 1990). In general, it was proved that aberrant expression of
oncogenes or EGF-receptors was associated with Tyr-phosphoryla-
tion (Reynolds et al, 1989; Takeshima et al, 1991) and that pTyr-
proteins are deeply related to cell cycle regulation (Yaacov et al,
1991). Furthermore, increase of pTyr-proteins might correlate with
the morphological transformation of tumour cells (Hamaguchi et
al, 1988). Clinically, it was reported that overexpression of pTyr-
proteins 100–130 kDa in molecular weight might predict shor-
tened survival of lung cancer patients (Nishimura et al, 1996).
Thus, a close relationship between tyrosine phosphorylation and
biological characteristics of the malignant tumours has been specu-
lated upon. However, there are few reports using clinical materials
concerning pTyr-proteins in cancer cells.
In this context, we attempted to clinicopathologically evaluate
the relationship between tyrosine phosphorylation and tumour
characteristics using surgically resected materials of non-small cell
lung cancer (NSCLC), and to discuss the clinical signiﬁcance of
pTyr-proteins in NSCLC.
MATERIALS AND METHODS
Preparation of surgically-resected tumours and normal
peripheral lung tissues
Clinical materials were obtained from 96 patients with NSCLC,
resected at the Department of Surgery, Tokyo Medical University
from October 1997 to May 1999. All specimens were collected from
cancerous tissues and normal peripheral lung tissues located far
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www.bjcancer.comfrom the cancerous lesion in the same lobe. The cancerous tissue
materials (1061063 mm in size) were collected from relatively
near the margin of the primary lesions to avoid both necrosis
and scar tissue. After tissue collection, inhibition of disphosphory-
lated kinases is immediately necessary. Therefore, tissue-materials
were incubated in 1 mM orthovanadate solution at 200 mmHg
for 5 min (Akimoto et al, 1998). After inhibition of disphosphory-
lated kinases, materials were acetone-ﬁxed and parafﬁn-embedded
(Sato et al, 1986). Sample preparation (the inhibition of dispho-
sphorylated kinases) was started within 30 min after the surgical
resection.
The 96 cases were diagnosed pathologically as adenocarcinoma
(62 cases), squamous cell carcinoma (31 cases), and large cell carci-
noma (three cases). Furthermore, adenocarcinoma and squamous
cell carcinoma was histopathologically classiﬁed as well, moderately
and poorly differentiated. Tumours were classiﬁed according to the
histological subgroups recommended by the World Health Organi-
zation (Travis et al, 1999) and staged by the tumour–nodal
involvement–metastasis (TNM) system according to the UICC
TNM classiﬁcation, ﬁfth edition (Sobin and Wittekind, 1997).
Immunohistochemical staining
The surgically resected specimens were stained immunohistochemi-
cally using an avidin-biotin peroxidase complex (ABC) method
(Akimoto et al, 1998). We used a mouse monoclonal antibody
clone 4G10 (VEC, NY, USA) (Druker et al, 1989; Cohen et al,
1990; Kanakura et al, 1991) for the detection of pTyr-proteins,
and anti-proliferating nuclear antigen (PCNA) mouse monoclonal
antibody PC10 (DAKO, Copenhagen, Denmark) for the detection
of proliferating activity of tumour cells. We evaluated pTyr-
proteins and PCNA using consecutive slices of tissues.
Expression levels of the tyrosine phosphorylation and
cell proliferation
Epithelial cells with cytoplasmic staining were judged as the pTyr-
proteins-rich cells when pTyr-proteins were evaluated. Cases were
classiﬁed into three groups according to the frequency of positive
cells: high expression (High), more than 68% (mean+standard
deviation (s.d)) positive cells; intermediate expression (Int), 9–
68% (mean+s.d.) positive cells; and low expression (Low), less
than 8% (mean+s.d.) positive cells.
Cell proliferating ability was evaluated using the PCNA labelling
index of positive nuclear staining cells.
Western blot and immunodetection of pTyr-proteins
Disphosphorylated kinases-inhibited materials of human lung
cancer and normal peripheral lung were subjected to 7.5% SDS-
polyacrylamide gel electrophoresis as described previously (Laemm-
li, 1970; Weiner et al, 1990; Kanakura et al, 1991), and proteins were
transferred electrophoretically to Immobilon PVDF membrane
(Millipore). PTyr-proteins on the membrane were immunodetected
with monoclonal antibody (clone 4G10) and an enhanced chemilu-
minescence (ECL) western detection reagents kit (Amersham, Little
Chalfont, Buckinghamshire, UK) (Kaufmann et al, 1987; Hoffman
and Jump, 1989).
Statistical analysis
Statistical analysis of the data was performed by Student’s t-test. The
Kaplan–Meier method was used to estimate the disease-free survi-
val probability for each group. The log rank test was used to
compare survival curves. Differences were considered statistically
signiﬁcant when the P-value was less than 0.05. Also, the inﬂuence
of variables on postoperative disease-free survival was assessed using
Cox’s proportional hazard model. The following variables were used
in the Cox regression: t-factor, n-factor, lymphatic invasion, vascu-
lar invasion and pTyr-protein expression levels. A value of less than
0.05 was considered to indicate a statistically signiﬁcant difference.
RESULTS
pTyr-proteins expression
The features of immunohistochemical staining are shown in Figure
1. Cells with pTyr-proteins were detected in 71 cases (74.0%) out
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Figure 1 Immunohistochemical staining of phosphorylated tyrosine-containing proteins (pTyr-proteins) (A) Normal peripheral lung tissue; B–D: non-
small cell lung cancer. (B) Low expression, (C) intermediate expression, (D) high expression.
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other hand, only 13 (13.6%) normal peripheral lung tissues showed
positive cells. Furthermore, 10 of these 13 cases possessed less than
20% positive cells.
Also, we detected pTyr-proteins in Western-blot analysis (Figure
2). Cancerous tissues expressed pTyr-proteins showing various
molecular weight (120, 85, 75, 45, and 30 kDa) in the cancerous
tissues. On the contrary, a few pTyr-proteins were expressed in
the normal peripheral lung.
Figure 3 shows the expression levels of pTyr-proteins in the
normal and malignant tissues. There was a statistically signiﬁcant
difference in pTyr-protein expression between normal and cancer-
ous tissues (P50.0001).
Tyrosine phosphorylation and clinicopathological features
Table 1 shows the relationship between the expression levels of
pTyr-proteins and clinicopathological factors. No statistically
signiﬁcant differences were found in any clinicopathological
factors. However, there was a statistically signiﬁcant difference
among different degrees of histopathological differentiation of
NSCLC (P50.0001 between well and moderate differentiation,
P50.0001 between well and poor differentiation and P=0.0367
between moderate and poor differentiation).
The relationship between expression levels of
pTyr-proteins and cell proliferation
Figure 4 shows the relationship between the expression levels of
pTyr-proteins and cell proliferating ability using the PCNA label-
ling index in NSCLC tissues. There was a statistically signiﬁcant
difference between each group (P(Low, High)50.0001; P(Low, Int)
50.0001; P(Int, High)50.0001).
The expression levels of pTyr-proteins and the disease-free
survival
Postoperative follow-up-periods in all cases were more than 25
months in this study. Figure 5 shows the disease-free survival
curves for each expression levels of pTyr-proteins. There was a
statistically signiﬁcant difference between cases with low expression
and intermediate expression (P=0.0028), and cases with low
expression and high expression (P=0.0002) (Figure 5a). Only in
stage I cases was there a statistically signiﬁcant difference between
cases with low expression and intermediate expression (P=0.0188),
and cases with low expression and high expression (P=0.0006)
(Figure 5b).
The contribution to postoperative disease-free survivals
All variables (t-factor, n-factor, lymphatic invasion, vascular inva-
sion and pTyr-protein expression levels) were included in a
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Figure 2 Detection of pTyr-proteins in human tissues of peripheral lung
and lung cancer using Western blot analysis. We detected pTyr-proteins
with various molecular weights. Arrowheads showed pTyr-proteins with
approximately 120, 85, 75, 45 and 30 kDa in molecular weight. N: normal
peripheral tissue; T: cancerous tissue. Case 1: Adenocarcinoma; Case 2:
Squamous cell carcinoma.
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Figure 3 The relationship of pTyr between normal (mean+s.d.:
2.26+8.03) and tumour (mean+s.d.: 38.13+30.15) tissues was showed.
The Student’s t-test was used to estimate the tyrosine phosphorylation
levels.
Table 1 Relationship between expression of pTyr-proteins and clinico-
pathological factors in the 96 patients with NSCLC
Clinicopathological factors Mean+s.d.
Statistical
analysis*
Age 560 37.37+29.35
61*70 31.18+31.57
470 43.69+28.77 N.S
Sex male 37.37+28.43
female 40.83+32.95 N.S
Histopathological Adenocarcinoma 38.36+33.00
types Squamous cell ca 39.16+25.06
Large cell ca 23.80+16.83 N.S
Histopathological Well 13.90+26.66 P
1
differentiation Moderate 42.44+24.78 P
3
Poor 57.94+24.85 P
2
t-factors t1 31.57+30.77
t2 42.25+30.50
t3 43.78+22.91
t4 12.50+17.68 N.S
n-factors n0 36.71+30.67
n1 34.22+35.09
n2 47.76+25.77
n3 30.00+28.28 N.S
Lymphatic invasion (7) 38.49+31.43
(1+) 32.37+25.48
(2+) 54.56+30.87 N.S
Vesal invasion (7) 35.31+31.69
(1+) 38.81+29.09
(2+) 45.69+25.14 N.S
Histopathological I 34.75+31.62
stage II 52.00+21.46
IIIa 49.63+25.18
IIIb 21.25+21.75 N.S
*Statistical analysis was performed using Student’s t-test. N.S=not signiﬁcant.
P
150.0001; P
2=0.0367; P
350.0001.
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stepwise analysis, n-factor, vascular invasion and pTyr-proteins
expression level revealed statistical signiﬁcance. PTyr-proteins
expression levels were found to be an independent prognostic indi-
cator as well as n-factor and vascular invasion (Table 2A). In the
investigation of only stage I-cases pTyr-protein expression levels
were signiﬁcantly related to disease-free survival. In the stepwise
analysis no other variable revealed statistical signiﬁcance (Table
2B).
DISCUSSION
Primary lung cancer is an aggressive and highly malignant tumour
frequently having an extremely miserable outcome. Even in lung
cancers diagnosed as pathological stage I, approximately 30%
relapse mainly due to distant metastasis. At present pathological
staging based on TNM classiﬁcation is the most reliable method
to estimate patient prognosis, but the results are not satisfactory.
Biological markers reﬂecting tumour characteristics might enhance
evaluation of patient prognosis.
It is now known that carcinogenesis and tumour progression are
related to the accumulation of mutations of oncogenes and tumour
supressor genes (Fearon and Vogelstein, 1990; Sozzi et al, 1992;
Sundaresan et al, 1992; Hirano et al, 1994). Nearly half of known
oncogenes encode tyrosine kinases and are distributed throughout
whole human cells. Yet, there are a few reports concerning the rela-
tionship between the expression of pTyr-proteins and human
cancer (Hunter and Sefton, 1980; Shibamoto et al, 1994). Accord-
ing to a previous investigation using immunoprecipitation, the
overexpression of tyrosine-phosphorylated 100–130 kDa proteins
correlated with poor prognosis in lung cancer cases (Nishimura
et al, 1996; Imaizumi et al, 1997). We also detected these 100–
130 kDa pTyr-proteins by Western blot analysis of surgically
resected materials of both normal and cancerous tissues of the lung
(Figure 2). However, the high expression of these proteins is not
always associated with high malignancy of lung cancer. Also,
pTyr-proteins with more varied molecular weights, including lower
molecular weights, were detected in malignant tissues. There is a
possibility that the pTyr-proteins with relatively lower molecular
weight may belong to the other kinds of tyrosine kinase including
src family and its related proteins. Therefore, we attempted to
immunohistohemically evaluate all pTyr-proteins in surgically
resected NSCLC tissues as well as in normal peripheral lung tissues
from the same lobe, but distant from the primary lesion.
In only 13 out of 96 (13.6%) normal peripheral lung tissues
were pTyr-proteins detected, even at a low expression level. We
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Figure 4 The relationship between pTyr expression levels and PCNA
(mean+s.d.: p-Tyr(Low), 7.08+8.79; p-Tyr(Int), 36.74+19.31; p-Tyr(High),
68.57+11.20) was shown. The statistical analysis was performed using Stu-
dent’s t-test.
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Figure 5 Actuarial curves for disease-free survival of patients with
NSCLC according to the levels of pTyr-proteins. (A) All patients with
NSCL; (B) Stage I-patients with NSCLC. The Kaplan–Meier method
was used to estimate the survival distribution for each group. The log rank
test was used to evaluate the equality of the survival curves.
Table 2 Multivariate analysis of postoperative survival with the Cox proportional hazards model
Variable DF Estimate Std err w
2 Prob w
2 Hazard ratio 95% CI
(A) All patients with NSCLC
pTyr % 1 0.55749 0.25278 4.86377 0.02743 1.74628 1.06401–2.86605
n-factor 1 0.63737 0.17111 13.87437 0.0002 1.89151 1.35255–2.64521
Vesal invasion 1 1.10366 0.23191 22.64869 0.00000 3.01519 1.91388–4.75023
(B) Stage I-patients with NSCLC
pTyr % 1 0.89056 0.33362 7.12576 0.0076 2.4365 1.26704–4.68535
Lymphatic invasion 1 0.54059 0.38895 1.93175 0.16457 1.71701 0.80113–3.67998
Vesal invasion 1 0.43819 0.33874 1.6733 0.19582 1.54989 0.79793–3.01051
DF: degree of freedom; Std err: standard error; Prob: probability; CI: conﬁdence interval.
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maintaining normal functions in normal cells, even if generally
the expression levels are extremely low compared with the expres-
sion level in malignant neoplastic tissues. Indeed, we also detected
very low levels of pTyr-proteins even in ciliated bronchial epithe-
lium as well as alveolar cells (data not shown).
In lung-cancerous tissues various expression levels of pTyr-
proteins were detected in 71 out of 96 (74.0%) lung cancer materi-
als. Furthermore, as the degree of histopathological differentiation
of cancerous tissues became poorer, the expression levels of pTyr-
proteins increased. These results support the concept that overex-
pression of pTyr-proteins may be associated with malignant
transformation and progression of lung cancer. We also obtained
data indicating a positive relationship between elevations of
pTyr-proteins and increased cell proliferation ability. Most growth
factor receptors, including epidermal growth factor (EGF) receptor,
platelet derived growth factor (PDGF) receptor and HER2/neu
possesses tyrosine-kinase activity and have been reported to be
closely associated with cell proliferation (Kokai et al, 1988; Rahimi
et al, 1998; Tanaka et al, 1998; Liu et al, 2000). In this study, we
evaluated cell proliferation immunohistochemically in terms of
the labelling index of PCNA using the consecutive slice of the same
materials used for evaluation of pTyr-proteins. A closely signiﬁcant
relationship between pTyr-proteins and PCNA was recognised
(Figure 4). Therefore, our data supported that the mechanisms
of the elevation of pTyr-proteins are probably related to cell
growth though several pathways.
Also, a statistically signiﬁcant difference in the expression levels
of pTyr-proteins according to the level of histopathological differ-
entiation was recognised. At present, histopathological
differentiation is diagnosed by experienced pathologists mainly
based on histopathological and cellular structures. In general,
poorly differentiated tumours show large differences in cellular
shapes and sizes and loss of histological structures. Even though
histopathological differentiation is one of the most important
factors reﬂecting tumor malignancy, the criteria of histopathologi-
cal differentiation are largely subjective. a- and b-catenins are
essential for tight cell-cell adhesion through e-cadherin, because
the cadherin-catenine complex combines with actin ﬁlaments.
The deletion of these molecules causes tumour cells not only to
lose the function of cell-cell adhesion but to change cellular forma-
tion (Shimoyama et al, 1992). In addition, it is already known that
the phosphorylation of b-catenins induce dysfunction of e-cadherin
(Matsuyoshi et al, 1992; Hamaguchi et al, 1993). Therefore, there is
a possibility that phosphorylation may be related to morphological
alterations.
The clinical impact of this study may be to clarify the signiﬁcant
relationship between the expression of pTyr-proteins and survival
probability after surgery. Our ﬁndings indicate that overexpression
of pTyr-proteins is associated with poor disease-free survival in
spite of the absence of correlation with clinicopathological factors.
At the same time, Cox regression multivariate analysis indicated
that vascular invasion, n-factor and pTyr-proteins were unfavour-
able factors. Furthermore, this analysis showed pTyr-proteins
overexpression to be only one signiﬁcant prognostic-factor among
stage I NCSLC cases. In this context, there is a high possibility that
pTyr-protein overexpression must be deeply associated with malig-
nant biological characteristics, and that several mechanisms of
phosphorylation in cancerous cells are responsible for poor prog-
nosis in the patients with NSCLC. As new therapeutic strategies,
adjuvant therapy seems to be needed for stage I-cases with pTyr-
proteins overexpression. In addition, world-wide clinical trials
using a tyrosine kinase inhibitor seems to be obtaining favourable
results. When this kind of medicine will be used clinically in the
near future, the evaluation of expression levels of pTyr-proteins
might be valuable for the prediction of effectiveness of tyrosine
kinase inhibitors.
This study suggests that tyrosine-phosphorylation is related to
histopathological differentiation, cell proliferating ability and poor
prognosis. According to previous reports, a few independent
survival markers (Bcl-2 for longer survival, and mutant-p53 for
shorter survival) were shown (Ohsaki et al, 1996; Moldvay et al,
2000). Our study did not focus on the evaluation of a speciﬁc
molecule. The evaluation of pTyr-proteins reﬂected the expression
levels and activities of various kinds of tyrosine-kinase, cell prolif-
eration ability and cell to cell adhesion indirectly and
comprehensively. In addition, pTyr-proteins expression levels were
independent of pathological TNM-staging. Therefore, we conclude
that evaluation of pTyr-proteins is valuable to more fully under-
stand the biological characteristics of tumour cells, and we believe
that it may be valuable for constructing the most appropriate
therapeutic strategy.
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